67th American Society of Hematology Annual Meeting (ASH 2025)
Fueled by Connections to Transform Rare Diseases™
Agios at ASH 2025
New data on Agios’ first-in-class pyruvate kinase (PK) activator, mitapivat, will be featured in oral and poster presentations highlighting its potential for patients with thalassemia, sickle cell disease, and PK deficiency – serious rare blood disorders with few or no treatment options.
Agios will also showcase research from two company-supported advisory councils, each comprised of patients, caregivers, advocates, and physicians, to help advance the scientific understanding of these debilitating and life-threatening rare diseases.
In total, 10 presentations and publications led by Agios and external collaborators will be shared at ASH 2025.
Visit the company’s booth (#1661) onsite.
Agios ASH 2025 Data Room & Resources
Agios ASH 2025 Data Room
View Agios- and collaborator-led presentations and publications shared at ASH 2025.
Medical & Scientific Resources
Access educational and scientific resources related to Agios’ investigational and approved medicines. This site is for healthcare professionals only.
PYRUKYND® (mitapivat)
Learn more about Agios’ FDA-approved PK activator for adults with PK deficiency. This site is for U.S. healthcare professionals only.
Rethink Thalassemia
Find out more about the subtypes of thalassemia, its risks and complications, and how to manage the disease. This site is for U.S. healthcare professionals only.
Know Pyruvate Kinase (PK) Deficiency
Access information on PK deficiency and how to manage the disease, disease burden, and importance of management. This site is for U.S. healthcare professionals only.
12/25